Sellas Life Sciences
3 articles
Industry NewsSellas Life SciencesBioSpace
Sellas' GPS vaccine clears Phase 3 REGAL in AML, with an accelerated-approval talk next
- Phase 3 REGAL randomized 126 AML patients in second or later remission to galinpepimut-S maintenance or investigator's-choice best available therapy.
- Median overall survival was 24 months versus 14.7 months, a 41% lower risk of death, described as statistically significant; hazard ratio and p-value were not given.
- Safety was mostly mild injection-site reactions. Sellas will meet the FDA about accelerated approval, with a filing planned for the first half of next year.
Read this against the company's own history: this trial was long expected to miss, so the first thing to test is how the final analysis was triggered and whether the open-label design and a small event count flatter the result. A 9-month median gain against best available therapy is large for a vaccine, but without a hazard ratio, confidence interval or secondary endpoints, regulators will be the real judge. The comparator, a mixed best-available arm, is the weak spot to watch at the conference data.
Industry NewsSellas Life SciencesSTAT News
Sellas's Delayed AML Trial Looks Poised to Miss Survival Goal, Analysis Suggests
- GPS (galinpepimut-S), Sellas Life Sciences' cancer immunotherapy, is being tested in the Phase 3 REGAL trial in acute myeloid leukemia (AML) patients who are in a second remission after at least two prior lines of therapy.
- REGAL enrolled more than 100 patients; its primary endpoint is overall survival versus standard of care.
- The trial has an event-driven design requiring 80 patient deaths to trigger the final survival analysis; as of the latest count, 72 of the 80 required events had occurred.
- Completion has slipped nearly a year past original timelines — a pace a Sept. 17, 2026 STAT News analysis reads as concerning, since slower-than-expected death accrual can hint that a drug isn't extending survival as hoped.
- This failure prediction is informed analyst/columnist speculation based on trial mechanics and the delay pattern, not an official, sponsor-confirmed readout.
Trial-watchers read event-driven Phase 3s by the clock, not the topline: REGAL needs 80 deaths to unlock its survival readout, and sitting at 72/80 nearly a year behind schedule is the kind of pattern sophisticated observers flag as a soft signal, not a verdict. Slower death accrual can mean GPS is genuinely extending survival — the optimistic read — but it's equally consistent with sluggish enrollment, extended follow-up, or censoring quirks unrelated to efficacy; event-driven mechanics are inherently ambiguous until the data actually locks. What is real: this is a binary, pipeline-defining catalyst for a small-cap with limited depth beyond GPS in AML. A negative readout would sharply narrow strategic options — partnership leverage, cash runway, follow-on financing — while a positive one could be a rare re-rating story. Until REGAL formally reads out, this remains informed speculation, not a confirmed result.
Industry NewsSELLAS Life SciencesSTAT News
SELLAS's Phase 3 AML Immunotherapy Trial Expected to Fail, Per STAT Report
- SELLAS Life Sciences' galinpepimut-S (GPS) is a WT1-targeting peptide immunotherapy.
- The pivotal Phase 3 REGAL trial enrolled more than 100 acute myeloid leukemia (AML) patients in second remission, randomized to GPS versus physician's choice of treatment, with the primary goal of demonstrating improved overall survival.
- The trial is event-driven, requiring 80 patient deaths before a final analysis can be conducted; reporting indicates the event count is nearing that threshold.
- The trial's conclusion has been delayed by nearly a year.
- Per STAT News reporting by biotech columnist Adam Feuerstein, the long-delayed REGAL trial is expected to end in failure, with GPS not expected to show a survival benefit over standard of care.
- A negative outcome would represent a significant setback for SELLAS's lead clinical program.
Nearly a year late to hit its death-count threshold — that delay is the real signal in this story, not a footnote. Event-driven trials that take longer than planned to accrue events are rarely good news: if the treatment arm were meaningfully extending survival, events would accrue slower and the delay would read as encouraging, not ominous. That REGAL is reportedly headed for failure fits a pattern, not an anomaly. This is SELLAS's lead asset, so a negative confirmatory readout isn't a pipeline setback — it's closer to an existential one for a small-cap with limited runway and few near-term catalysts to fall back on. It also adds another data point to WT1-targeting peptide vaccines' long, mostly disappointing history in AML, a mechanism that has struggled to translate immunogenicity into survival benefit across multiple sponsors. Expect a sharp reassessment of remaining pipeline value, cash runway, and financing options once/if this is confirmed.